KM4BI KM4BI

Palantir's AIPCon 10, Ramp Hits $44B, 60 Minutes Eyes Rogan | Diet TBPN

Diet TBPN connects AI biosecurity, renewed biotech momentum, Ramp’s major raise, and media signals around Rogan.

This Diet TBPN episode moves through several current signals: an open letter on AI-linked biosecurity, renewed attention on biotech, Ramp’s latest financing, and cultural markers around Joe Rogan and cars.

Biosecurity and AI

The hosts explain why nucleic-acid synthesis is becoming a regulatory topic: viral sequences have been published and later reconstructed from data, and AI may lower the barrier further. The letter backed by AI, biotech, and synthesis leaders calls for mandatory screening, customer verification, and recordkeeping.

Biotech and capital

The episode notes that biotech is regaining momentum after a difficult period, with Isomorphic Labs, New Limit, Retro, Altos Labs, and Coefficient Bio in the discussion. The hosts are careful about scale: activity is picking up, but it is not yet comparable to the largest AI or semiconductor cycles.

Ramp, tokens, and corporate finance

Ramp raised $750 million at a $44 billion valuation. The discussion centers on execution speed, comparisons with PayPal, and the idea that token spend is becoming a new financial line item to manage alongside people and vendors.

Other signals

Sabi appears as a leaked BCI bet with claimed B2B traction, Goldman projects a sharp rise in xAI’s AI revenue, Benchmark launches its first dedicated growth fund, and 60 Minutes is reportedly considering Joe Rogan. The broader theme: AI, capital, biotech, and media keep shifting into each other’s lanes.

Source